Clinical trialsCompany release

Aptevo presents preclinical CD40 multispecific data for three solid-tumour candidates at SITC 2026

🇺🇸 Aptevo Therapeutics Inc. (APVO) · Mon 09 Nov 2026

Laboratory data for APVO451, APVO452 and APVO711 were shown at SITC on 7 November; the company expects two molecules to enter IND-enabling studies in 2027.

Aptevo Therapeutics announced on 9 November that it had presented preclinical data at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting on 7 November. The data cover three CD40-based multispecific candidates in solid tumours: APVO451, APVO452 and APVO711.

According to the company, APVO451 and APVO452, which combine CD40 activation with T-cell engagement, drove tumour-cell killing in laboratory experiments under immunosuppressive conditions. APVO711, which pairs CD40 activation with PD-L1 blockade, activated immune cells.

Aptevo said two of the preclinical molecules are expected to enter IND-enabling studies in 2027. The summary available does not specify which two, and no further detail on study design, models or quantitative results was provided.

No regulator action was reported. All findings are preclinical and come from the company's own announcement; they say nothing about safety or efficacy in patients.

What it means for your team

  • The programmes are preclinical; no regulatory submission or agency interaction has been reported, so there is no immediate regulatory impact.
  • IND-enabling studies, expected in 2027 for two molecules, are the next milestone to watch; an IND application would follow only after that work.
  • Pharmacovigilance and quality teams have no actions at this stage, as no human data or clinical supply are involved.
  • Details on which candidates advance and on the underlying data would be needed before assessing the competitive position in CD40 and PD-L1 approaches.

Company's press release (SEC filing): Aptevo Therapeutics Inc. ↗

Article written by VigiEye from the official source (Aptevo Therapeutics Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →